Effects of bacteriocins on methicillin-resistant Staphylococcus aureus biofilm

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5572-5579

  Okuda, Ken Ichi ^a   Zendo, Takeshi ^b   Sugimoto, Shinya ^a   Iwase, Tadayuki ^a   Tajima, Akiko ^a   Yamada, Satomi ^a   Sonomoto, Kenji ^b   Mizunoe, Yoshimitsu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOCIN; LACTICIN Q; NISIN; NISIN A; NUKASIN ISK 1; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; BACTERIAL CELL; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; BIOFILM; CHANNEL GATING; DRUG EFFECT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PLANKTON; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIOCINS; BIOFILMS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; NISIN; PLANKTON; PORE FORMING CYTOTOXIC PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; VANCOMYCIN;

EID: 84885919574     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00888-13     Document Type: Article

References (44)

1. Flemming HC, Wingender J. 2010. The biofilm matrix. Nat. Rev. Microbiol. 8:623-633.
2. Sugimoto S, Iwamoto T, Takada K, Okuda K, Tajima A, Iwase T, Mizunoe Y. 2013. Staphylococcus epidermidis Esp degrades specific proteins associated with Staphylococcus aureus biofilm formation and hostpathogen interaction. J. Bacteriol. 195:1645-1655.
3. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
4. Melchior MB, Fink-Gremmels J, Gaastra W. 2006. Comparative assessment of the antimicrobial susceptibility of Staphylococcus aureus isolates from bovine mastitis in biofilm versus planktonic culture. J. Vet. Med. B Infect. Dis. Vet. Public Health 53:326-332.
5. Vlastarakos PV, Nikolopoulos TP, Maragoudakis P, Tzagaroulakis A, Ferekidis E. 2007. Biofilms in ear, nose, and throat infections: how important are they? Laryngoscope 117:668-673.
6. Kania RE, Lamers GE, Vonk MJ, Dorpmans E, Struik J, Tran Ba Huy P, Hiemstra P, Bloemberg GV, Grote JJ. 2008. Characterization of mucosal biofilms on human adenoid tissues. Laryngoscope 118:128-134.
7. Donlan RM. 2001. Biofilm formation: a clinically relevant microbiological process. Clin. Infect. Dis. 33:1387-1392.
8. Cotter PD, Ross RP, Hill C. 2013. Bacteriocins-a viable alternative to antibiotics? Nat. Rev. Microbiol. 11:95-105.
9. Cotter PD, Hill C, Ross RP. 2005. Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 3:777-788.
10. Chatterjee C, Paul M, Xie L, van der Donk WA. 2005. Biosynthesis and mode of action of lantibiotics. Chem. Rev. 105:633-684.
11. Nagao J, Asaduzzaman SM, Aso Y, Okuda K, Nakayama J, Sonomoto K. 2006. Lantibiotics: insight and foresight for new paradigm. J. Biosci. Bioeng. 102:139-149.
12. Rogers LA. 1928. The inhibiting effect of Streptococcus lactis on Lactobacillus bulgaricus. J. Bacteriol. 16:321-325.
13. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl HG, de Kruijff B. 1999. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286:2361-2364.
14. Breukink E, van Heusden HE, Vollmerhaus PJ, Swiezewska E, Brunner L, Walker S, Heck AJ, de Kruijff B. 2003. Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J. Biol. Chem. 278:19898-19903.
15. Hsu ST, Breukink E, Tischenko E, Lutters MA, de Kruijff B, Kaptein R, Bonvin AM, van Nuland NA. 2004. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 11:963-967.
16. Sashihara T, Kimura H, Higuchi T, Adachi A, Matsusaki H, Sonomoto K, Ishizaki A. 2000. A novel lantibiotic, nukacin ISK-1, of Staphylococcus warneri ISK-1: cloning of the structural gene and identification of the structure. Biosci. Biotechnol. Biochem. 64:2420-2428.
17. Islam MR, Nishie M, Nagao J, Zendo T, Keller S, Nakayama J, Kohda D, Sahl HG, Sonomoto K. 2012. Ring A of nukacin ISK-1: a lipid IIbinding motif for type-A(II) lantibiotic. J. Am. Chem. Soc. 134:3687-3690.
18. Asaduzzaman SM, Nagao J, Iida H, Zendo T, Nakayama J, Sonomoto K. 2009. Nukacin ISK-1, a bacteriostatic lantibiotic. Antimicrob. Agents Chemother. 53:3595-3598.
19. Fujita K, Ichimasa S, Zendo T, Koga S, Yoneyama F, Nakayama J, Sonomoto K. 2007. Structural analysis and characterization of lacticin Q, a novel bacteriocin belonging to a new family of unmodified bacteriocins of gram-positive bacteria. Appl. Environ. Microbiol. 73:2871-2877.
20. Yoneyama F, Imura Y, Ohno K, Zendo T, Nakayama J, Matsuzaki K, Sonomoto K. 2009. Peptide-lipid huge toroidal pore, a new antimicrobial mechanism mediated by a lactococcal bacteriocin, lacticin Q. Antimicrob. Agents Chemother. 53:3211-3217.
21. Yoneyama F, Imura Y, Ichimasa S, Fujita K, Zendo T, Nakayama J, Matsuzaki K, Sonomoto K. 2009. Lacticin Q, a lactococcal bacteriocin, causes high-level membrane permeability in the absence of specific receptors. Appl. Environ. Microbiol. 75:538-541.
22. Zetola N, Francis JS, Nuermberger EL, Bishai WR. 2005. Communityacquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect. Dis. 5:275-286.
23. Aso Y, Okuda K, Nagao J, Kanemasa Y, Thi Bich Phuong N, Koga H, Shioya K, Sashihara T, Nakayama J, Sonomoto K. 2005. A novel type of immunity protein, NukH, for the lantibiotic nukacin ISK-1 produced by Staphylococcus warneri ISK-1. Biosci. Biotechnol. Biochem. 69:1403-1410.
24. Pag U, Oedenkoven M, Papo N, Oren Z, Shai Y, Sahl HG. 2004. In vitro activity and mode of action of diastereomeric antimicrobial peptides against bacterial clinical isolates. J. Antimicrob. Chemother. 53:230-239.
25. Horsburgh MJ, Aish JL, White IJ, Shaw L, Lithgow JK, Foster SJ. 2002. SigmaB modulates virulence determinant expression and stress resistance: characterization of a functional rsbU strain derived from Staphylococcus aureus 8325-4. J. Bacteriol. 184:5457-5467.
26. Ruhr E, Sahl HG. 1985. Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. Antimicrob. Agents Chemother. 27:841-845.
27. Demel RA, Peelen T, Siezen RJ, De Kruijff B, Kuipers OP. 1996. Nisin Z, mutant nisin Z and lacticin 481 interactions with anionic lipids correlate with antimicrobial activity. A monolayer study. Eur. J. Biochem. 235: 267-274.
28. van Kraaij C, Breukink E, Noordermeer MA, Demel RA, Siezen RJ, Kuipers OP, de Kruijff B. 1998. Pore formation by nisin involves translocation of its C-terminal part across the membrane. Biochemistry 37: 16033-16040.
29. Yoneyama F, Ohno K, Imura Y, Li M, Zendo T, Nakayama J, Matsuzaki K, Sonomoto K. 2011. Lacticin Q-mediated selective toxicity depending on physicochemical features of membrane components. Antimicrob. Agents Chemother. 55:2446-2450.
30. Dufour A, Hindre T, Haras D, Le Pennec JP. 2007. The biology of lantibiotics from the lacticin 481 group is coming of age. FEMS Microbiol. Rev. 31:134-167.
31. Jack R, Benz R, Tagg J, Sahl HG. 1994. The mode of action of SA-FF22, a lantibiotic isolated from Streptococcus pyogenes strain FF22. Eur. J. Biochem. 219:699-705.
32. Wiedemann I, Benz R, Sahl HG. 2004. Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study. J. Bacteriol. 186:3259-3261.
33. Barna JC, Williams DH. 1984. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu. Rev. Microbiol. 38:339-357.
34. Stewart PS. 1998. A review of experimental measurements of effective diffusive permeabilities and effective diffusion coefficients in biofilms. Biotechnol. Bioeng. 59:261-272.
35. Daddi Oubekka S, Briandet R, Fontaine-Aupart MP, Steenkeste K. 2012. Correlative time-resolved fluorescence microscopy to assess antibiotic diffusion-reaction in biofilms. Antimicrob. Agents Chemother. 56: 3349-3358.
36. Jefferson KK, Goldmann DA, Pier GB. 2005. Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 49:2467-2473.
37. Pinho MG, Errington J. 2003. Dispersed mode of Staphylococcus aureus cell wall synthesis in the absence of the division machinery. Mol. Microbiol. 50:871-881.
38. Lunde CS, Rexer CH, Hartouni SR, Axt S, Benton BM. 2010. Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus. Antimicrob. Agents Chemother. 54:2198-2200.
39. Brown MR, Allison DG, Gilbert P. 1988. Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? J. Antimicrob. Chemother. 22:777-780.
40. Duguid IG, Evans E, Brown MR, Gilbert culture upon the susceptibility of Staphylococcus epidermidis to tobramycin. J. Antimicrob. Chemother. 30:803-810.
41. Duguid IG, Evans E, Brown MR, Gilbert P. 1992. Growth-rateindependent killing by ciprofloxacin of biofilm-derived Staphylococcus epidermidis; evidence for cell-cycle dependency. J. Antimicrob. Chemother. 30:791-802.
42. Schwartz C, Henrickson KJ, Roghmann K, Powell K. 1990. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J. Clin. Oncol. 8:1591-1597.
43. Carratala J, Niubo J, Fernandez-Sevilla A, Juve E, Castellsague X, Berlanga J, Linares J, Gudiol F. 1999. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob. Agents Chemother. 43:2200-2204.
44. Henrickson KJ, Axtell RA, Hoover SM, Kuhn SM, Pritchett J, Kehl SC, Klein JP. 2000. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial. J. Clin. Oncol. 18:1269-1278.